Though considered potential antibody alternatives, these reagents are more likely to succeed in new applications for which conventional tools are poorly suited.
A company researcher said the new structure could provide the chemical diversity needed to build a set of reagents targeting the full human proteome.
The bioinformatics startup has also invested in six other companies, committing $400 million to its data-sharing collaboration.
The company has identified markers of latent disease that it is now investigating to see if they could be useful for predicting progression to active infection.
The developer has presented clinical results that provide a base for completing development of a multi-protein test kit and conducting a clinical trial in advance of FDA submission.
The European Commission recently awarded the researchers €1.5 million to probe the mechanics of heart failure using proteomic, genomic, and epidemiological approaches.
The company this week published a study in JAMA describing the panel, which is intended for assessing the risk of adverse events in coronary heart disease patients.
The firm said it will use the funds to support development of new life science tools and clinical diagnostics based on its Somamer affinity agent technology.
While SomaScan is the company's main source of revenue, it continues to develop its Dx business and will launch its first test in the second half of 2016.
Under the agreement, BMS has access to the 1,310 reagents in the public version of SomaLogic's SOMAscan assay along with a number of custom-developed reagents.
Mary Beckerle has been removed as director of the Huntsman Cancer Institute in what one researcher refers to as a "coup," ScienceInsider reports.
Bill Gates tells the Telegraph that bioterrorism is a serious risk.
The March for Science is to take place tomorrow, and supporters are tapping their creative energies to create placards to carry.
CBS News reports that the White House Science Fair is to continue under President Donald Trump.